**Core tip:** This study sought to assess the feasibility and effectiveness of a novel application of percutaneous radiofrequency ablation in the treatment of biliary stent obstruction. We report a retrospective study with the results of percutaneous intraductal radiofrequency ablation in patients with biliary stent occlusion.

INTRODUCTION
============

The use of biliary self-expanding metallic stents (SEMSs) is an effective method for treating malignant biliary obstruction. However, with excessive tumor growth, tumor ingrowth, epithelial hyperplasia, biological film deposition and biliary sludge formation, the patency time of SEMSs is approximately 120 d\[[@B1]\]. The current management approaches for occluded SEMSs include mechanical cleaning and the insertion of a second stent (a covered SEMS, uncovered SEMS or plastic stent) *via* an endoscopic or percutaneous approach\[[@B2]\].

Recently, numerous clinical reports have demonstrated the safety and efficacy of using a novel radiofrequency (RF) ablation (RFA) catheter for endoscopic palliative procedures\[[@B3],[@B4]\]. There is a clinical need for an effective method of re-opening biliary stents that accounts for the limitations of an endoscope, particularly in cases involving hepatic hilar tumors or after gastrointestinal operations. Therefore, our research group investigated the treatment of biliary stent occlusion by percutaneous biliary RF.

MATERIALS AND METHODS
=====================

The Habib EndoHPB RF catheter for bipolar RFA (EMcision, United States) has a bipolar RF probe diameter of 8 Fr (2.6 mm), a length of 1.8 m, and a distance of 0.035 (COOK, United States) that allows to pass over a guide wire. The catheter has two ring electrodes separated by a distance of 8 mm and a leading edge that extends 5 mm beyond the distal electrode, and it can produce focal coagulation necrosis with a long diameter of more than 2.5 cm (Figure [1](#F1){ref-type="fig"}). This catheter can be used in the treatment of intraductal RF.

![The Habib EndoHPB bipolar radiofrequency ablation catheter with two bare metal electrodes 8 mm apart and the catheter head located 5 mm from the distal electrode.](WJG-23-1851-g001){#F1}

Patient characteristics
-----------------------

From July 2012 to March 2014, 43 patients with malignant biliary obstruction were recruited to this study. These patients underwent biliary stent (SEMSs, length 6-8 cm, diameter 1 cm, BARD, United States) treatment by percutaneous puncture (*n =* 24; stent patency range: 72-145 d) or endoscopic retrograde cholangiopancreatography (*n =* 19; stent patency range: 69-139 d). After treatment, the patients had fever, jaundice or symptoms of abdominal pain again (15-110 d). All patients underwent evaluation by CT or ultrasound to confirmed the proximal stent dilatation of the bile duct, an assessment of biliary stent occlusion, and dilatation of the intrahepatic bile duct, and routine preoperative examinations (routine blood parameters, liver function, renal function, and blood coagulation function). There were 24 cases of pancreatic carcinoma, 8 cases of bile duct carcinoma, 6 cases of hepatocellular carcinoma, and 5 cases of gallbladder cancer. The mean of patients' ages was 62 (47-82) years, and the male:female ratio was 26:17. Severe coagulopathy, heart failure and cardiac pacemaker implantation were contraindications for the procedures of this study. All patients signed an informed consent form before undergoing these procedures, which were approved by the relevant ethics committee.

Procedure details
-----------------

An Innova 3100 DSA (GE, United States) system was used for image-guided applications. A RITA 1500X RF generator (AngioDynamics, United States) was used for energy output. Under DSA guidance, contrast agent was injected into the bile duct, and the length of the stenosis was accurately determined by cholangiography. Using a guidewire technique, the catheter (C3 COOK, United States) was positioned in the area of the occlusion. In cases of complete biliary occlusion, it was necessary to form the guide wire into a loop using vascular catheters and a 5 Fr sheath (Terumo Japan) for support before passing the wire through the occlusion. If the 0.035 guide wire (Terumo Japan) remained unable to pass through the obstruction, the 0.018 guidewire (Boston, United States) was used. The location of the RF catheter was confirmed to avoid contact with the intestine. The RF generator was then connected using the following parameters: a frequency of 400 KHz, a power of 710 W, the mean ablation time of 90 s (range from 60 to 120 s), a stop time of 60 s, and a total output energy of 1200-3600 J (Figure [2](#F2){ref-type="fig"}). The ablation procedure was repeated 2 to 3 times across the length of the obstruction, and the catheter was removed simultaneously (Table [1](#T1){ref-type="table"}).

###### 

Procedure details

  ---------------------- ------------------
  Ablation time (s)      90 (62-150)
  Ablation repeats       3 (2-5)
  Ablation energy (J)    2474 (1200-3600)
  Stenosis length (mm)   35 (20-55)
  ---------------------- ------------------

Data are expressed as medians (range).

![Images for a 53-year-old female with carcinoma of the pancreatic head and a biliary stent implanted to treat obstructive jaundice 3.5 mo prior to this study for obstructive jaundice. An enhanced computed tomography (CT) scan showing bile duct obstruction (A); CT coronal reconstruction clearly showing stent obstruction (B); cholangiography revealing the complete obstruction of the biliary stent (C), the intraductal radiofrequency (RF) catheter in the position of obstruction (D), and internal and external drainage tube after RF (E); angiography indicating stent patency after procedure (F).](WJG-23-1851-g002){#F2}

The RFA catheter was then withdrawn. A drainage tube was implanted, stent patency was confirmed by angiography, and the bile duct was flushed with 0.9% saline to avoid stents restenosis. The indwelling drainage tube was removed 2-3 d after the operation, after which biliary stent patency was reconfirmed by cholangiography and the tract was plugged.

Evaluation and follow-up
------------------------

All patients underwent routine blood tests, liver and kidney function assessments, and determinations of serum amylase and C-reactive protein (CRP). And relevant data were recorded. Biliary tract dilatation was determined by CT, and biliary stent stenosis measurements, the number of ablations, and the ablation power output were recorded. The indwelling biliary drainage tube was removed 2 d after the procedures, and the tract was plugged with a gelatin sponge to prevent bile leakage into the peritoneal cavity. During the first week of follow-up, the patients were subjected to liver function tests and determinations of serum amylase and CRP. At 2 or 3 wk of follow-up, the patients were examined either as outpatients or during hospitalization, and liver function and bilirubin concentration changes were recorded. Ultrasound or low-dose CT was also performed to evaluate biliary tract dilatation, and survival times were recorded. Additionally, stent patency was evaluated by ultrasound or CT scan, with continuous bilirubin increase or pneumobilia considered to indicate stent obstruction.

Statistical analysis
--------------------

All study data were analyzed using SPSS 17.0 and GraphPad Prism 5 statistical software. The data are expressed as the median (range) or mean (± SD). Measurement and count data were evaluated using *t-*tests and χ^2^ tests, respectively. *P \<* 0.05 was regarded as statistically significant.

RESULTS
=======

All patients underwent successful intraductal RF in the stents, and cholangiography was performed to ensure stent patency after the procedure. The indwelling drainage tube was retained for 7 d after procedures in 2 cases, because of necrosis and cholestasis after procedure, and in the remaining 41 cases, the biliary drainage tube was removed 2 d after the procedure. Post-procedure cholangiography revealed stent patency. There were no cases requiring implanting another biliary stent or further percutaneous transhepatic drainage.

There were no procedure related complications per SIR reporting standards. And no cases of hemorrhage, bile duct perforation, bile leak, or pancreatitis were observed after the intraductal RF. Mild abdominal pain (*n =* 16) was the main symptom after procedure, and it can subside spontaneously in 36 h. One patient was lost to follow-up, and 3 patients with cachexia due to multiple organ failure died 1 mo after ablation. Intraoperative angiography indicated that the median length of the biliary stricture was 35 mm (range: 20-55 mm). The median number of intraductal RF was 3 times (range: 2-5 times), which was based on the location and degree of obstruction of the biliary stent. The median output power for the intraductal RF was 2474 J (range: 1200-3600 J), and cholangiography was used to measure the diameter of the biliary tract. The median diameter of the biliary stricture before and after procedure was 1 mm (range: 0-4 mm) *vs* 8.0 mm (range: 6.0-10.0 mm). The median stent patency duration was 107 d (range: 12-180 d). Figure [3](#F3){ref-type="fig"} presents Kaplan-Meier curves that reveal stent patency trends. Figure [4](#F4){ref-type="fig"} indicates pre- and post-procedure luminal diameters. The bilirubin levels before and after procedure were 63 ± 29 μmol/L *vs* 128 ± 65 μmol/L (*P \<* 0.05). Table [2](#T2){ref-type="table"} showed details about hepatic function metrics changes before and after procedure.

###### 

Biochemical parameters before and after the procedure

  **Parameters**       **Pre-ablation**   **Post-ablation (day 3)**   **Normal**
  -------------------- ------------------ --------------------------- ------------
  Bilirubin (μmol/L)   128 ± 65           63 ± 29                     0-21
  ALP (IU/L)           1240 ± 865         1032 ± 790                  30-130
  ALT (IU/L)           105 ± 58           79 ± 40                     \< 40
  GGT (IU/L)           747 ± 729          720 ± 625                   \< 55
  LDH (IU/L)           60 ± 84            311 ± 45                    0-250
  AST (IU/L)           98 ± 49            65 ± 34                     \< 40
  CRP (mg/L)           15 ± 8             12 ± 7                      0-5
  Amylase (IU/L)       80 ± 15            79 ± 12                     0-90

![Stent patency trends after procedure.](WJG-23-1851-g003){#F3}

![Luminal diameters before and after the procedure.](WJG-23-1851-g004){#F4}

DISCUSSION
==========

Obviously, with lengthened patient survival times, SEMS occlusion has become a common clinical situation. Although organic polymer-packaged SEMSs or methods to coat stents with nickel titanium alloy or other alloys could potentially be used instead of stainless steel or covered stents to address the issue of stent restenosis, experimental data have not supported this possibility\[[@B5],[@B6]\]. Rather, the data have indicated that these novel types of stents increase the incidence of pancreatitis and cholecystitis, leading to long-term inflammation and bile duct bleeding\[[@B7]-[@B9]\]. Khashab et al\[[@B10]\] tried to extend the stent patency time by changing the shape of the stent, but the results were not different from those for a conventional stent.

Once a stent is placed in the bile duct, an encrustation of amorphous material and bacteria (sludge) begins to accumulate on its surface. The major limitation to long-term biliary stenting is thus early stent occlusion, although early symptoms of stent obstruction are not typical. Pneumobilia in the intrahepatic biliary tree is present when there is reflux of gas from the bowel and can also be present after biliary stent occlusion. In this context, early improvement of biliary drainage is particularly important\[[@B11]\].

RF has been widely used to treat malignant solid tumors and has even become a standard treatment for certain inoperable tumors, such as liver cancer and lung cancer. Its safety and efficacy are well established. However, restricted to the traditional RF structure, the RF technology has never been used to treat malignant biliary obstruction. The use of this catheter risks indirect injury to adjacent organs and electrode-induced skin burns. In addition, the unpredictability of the electric current path reduces the ablation area. The use of RFA in the biliary tract is also limited due to the possibility of biliary fistulas and bile duct adhesion. A new bipolar catheter can avoid the aforementioned problems and has been demonstrated to be successful and safe for palliative therapy for malignant biliary occlusion\[[@B12]\].

Intraductal RF can delay tumor growth and retain the patency of SEMSs for a prolonged duration. In turn, the successful drainage leads to prolongation of survival time\[[@B13]\]. Khorsandi et al\[[@B14]\] subjected the EndoHPB catheter to extensive *in vivo* preclinical testing. A preliminary study using a pig model indicated that this catheter can be safely deployed in the context of SEMSs. In particular, intraductal RF treatment using this catheter causes the coagulative burning of intraductal tissues, but the heat associated with this burning will not damage surrounding tissue\[[@B15],[@B16]\]. Another single published ex-vivo porcine study sought to systematically evaluate the effect of intraductal RF at various power settings (5, 10, 15 and 20 W) and durations of treatment (60, 90 and 120 s) on freshly resected porcine livers\[[@B17]\]. In practice, setting the output power to 10 W and ablation time for 90 s, it performed safe and efficient (Table [1](#T1){ref-type="table"}). In the current study, none of patients exhibited pancreatitis or a biliary fistula due to heating.

An examination of endoscopic biliary RFA treatment in cases of malignant biliary obstruction and stent restenosis has confirmed the efficacy and safety of biliary RF technology\[[@B18]\]. Steel et al\[[@B3]\] specifically reported the endoscopic intraductal RF in 22 patients with malignant biliary obstruction. The examined cases included 10 patients with biliary SEMS restenosis (6 pancreatic cancer patients, 2 bile duct carcinoma patients, and 2 metastatic liver cancer patients) who underwent 13 intraductal RF treatments. The luminal diameter of the stenosis increased from a preoperative value of 1 mm to 5 mm after intraductal RF. The biliary stents remained open with a median patency duration of 119 d after procedures. Clinical research results have also demonstrated the effectiveness and safety of RF therapy for stent restenosis treatment in the biliary tract\[[@B19]\]. For patients with a history of gastrointestinal surgery, ERCP is considered a contraindication, but PTCD has no such limitation.

Intraductal RF *via* endoscopy has been used in the treatment of SEMS obstruction because of tumour ingrowth or overgrowth, which is a frequent complication. Mukund et al\[[@B19]\] specifically used intraductal RF to clear obstructed SEMSs. Both cases had extensive disease and showed radiological and biochemical evidence of improved drainage after intraductal RF application. However, the number of cases was too small to draw a definitive conclusion. Complication rates with both approaches appear to be comparable with those with the current standard ERC/PTD insertion and stenting in patients with malignant biliary disease\[[@B20],[@B21]\].

Research has indicated that RF technology has potential clinical applications in treating stenosis of the biliary tract, and endoscopic RFA treatment in cases of malignant biliary obstruction and in-stent restenosis has confirmed the efficacy and safety of intraductal RF technology\[[@B22]\]. Furthermore, in the case of obstruction of a previously deployed metal stent, which cannot be removed, this intraductal RF approach can clear the occlusion and restore the biliary flow without the insertion of a new stent inside the obstructed stent, thereby saving the cost of a second stent\[[@B23]\]. Intraductal RF also has the advantageous characteristics of being a repeatable procedure by ERCP and PTCD. Moreover, for obstructive jaundice with a history of gastrointestinal surgery, it is difficult to reach the site of bile duct obstruction by endoscopy\[[@B24]\].

There were no major complications in our patients. The RF catheter can be easily introduced to the biliary tract and accurately positioned at the stricture lesion. However, the dispute is that how to apply intraductal RF for different stent locations (the hilum or ampulla) and how to choose an appropriate approach (percutaneous RFA or endoscopic RFA) to avoid injury to the bile duct and surrounding structures\[[@B21],[@B25]\]. More clinical studies are required to guide clinical application.

The present study was a pilot feasibility study with obvious limitations. The number of patients enrolled was small. The follow-up duration may have been inadequate to demonstrate the long-term efficacy of this novel technique. Further studies are required to confirm our results.

COMMENTS
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Background
----------

The use of biliary self-expanding metallic stents is an effective method for treating malignant biliary obstruction. There is a clinical need for an effective method of re-opening biliary stents that accounts for the limitations of an endoscope, particularly in cases involving hepatic hilar tumors or after gastrointestinal operations. Therefore, our research group investigated the treatment of biliary stent occlusion by percutaneous biliary radiofrequency ablation (RFA).

Innovations and breakthroughs
-----------------------------

To assess the feasibility and effectiveness of a novel application of percutaneous RF for the treatment of biliary stents obstruction, the authors specifically report a retrospective study presenting the results of percutaneous intraductal RF in patients with biliary stent occlusion.

Applications
------------

This preliminary clinical study demonstrated that percutaneous intraductal RF is safe and effective for the treatment of biliary stent obstruction, increasing the duration of stent patency, although randomized controlled trials are needed to confirm the effectiveness of this approach.

Peer-review
-----------

In this manuscript, a total of 43 cases involving biliary obstruction caused by biliary stent stenosis were treated by placing an EndoHPB catheter into the stenosis and performing percutaneous transhepatic biliary RFA. The authors found that percutaneous internal biliary RFA is safe and effective for the treatment of biliary stent obstruction and increases the accumulation of stent patency time, although randomized controlled trials are needed to confirm the effectiveness of this approach.
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